DOCSLIB.ORG

Framework for Equitable Allocation of COVID-19 Vaccine (2020)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

THE NATIONAL ACADEMIES PRESS This PDF is available at http://nap.edu/25917 SHARE Framework for Equitable Allocation of COVID-19 Vaccine (2020) DETAILS 260 pages | 6 x 9 | PAPERBACK ISBN 978-0-309-68224-4 | DOI 10.17226/25917 CONTRIBUTORS GET THIS BOOK Helene Gayle, William Foege, Lisa Brown, and Benjamin Kahn, Editors; Committee on Equitable Allocation of Vaccine for the Novel Coronavirus; Board on Health Sciences Policy; Board on Population Health and Public Health Practice; Health FIND RELATED TITLES and Medicine Division; National Academies of Sciences, Engineering, and Medicine; National Academy of Medicine SUGGESTED CITATION National Academies of Sciences, Engineering, and Medicine 2020. Framework for Equitable Allocation of COVID-19 Vaccine. Washington, DC: The National Academies Press. https://doi.org/10.17226/25917. Visit the National Academies Press at NAP.edu and login or register to get: – Access to free PDF downloads of thousands of scientific reports – 10% off the price of print titles – Email or social media notifications of new titles related to your interests – Special offers and discounts Distribution, posting, or copying of this PDF is strictly prohibited without written permission of the National Academies Press. (Request Permission) Unless otherwise indicated, all materials in this PDF are copyrighted by the National Academy of Sciences. Copyright © National Academy of Sciences. All rights reserved. Framework for Equitable Allocation of COVID-19 Vaccine Framework for Equitable Allocation of COVID-19 Vaccine Helene Gayle, William Foege, Lisa Brown, and Benjamin Kahn, Editors Committee on Equitable Allocation of Vaccine for the Novel Coronavirus Board on Health Sciences Policy Board on Population Health and Public Health Practice Health and Medicine Division PREPUBLICATION COPY: UNCORRECTED PROOFS Copyright National Academy of Sciences. All rights reserved. Framework for Equitable Allocation of COVID-19 Vaccine THE NATIONAL ACADEMIES PRESS 500 Fifth Street, NW Washington, DC 20001 This activity was supported by contracts between the National Academy of Sciences and the Centers for Disease Control and Prevention and the National Institutes of Health (75N98020F00007). This project has been funded in whole or in part with federal funds from the Office of Science Policy, National Institutes of Health, U.S. Department of Health and Human Services under Contract No. HHSN263201800029I. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. International Standard Book Number-13: 978-0-309-XXXXX-X International Standard Book Number-10: 0-309-XXXXX-X Digital Object Identifier: https://doi.org/10.17226/25917 Additional copies of this publication are available from the National Academies Press, 500 Fifth Street, NW, Keck 360, Washington, DC 20001; (800) 624-6242 or (202) 334-3313; http://www.nap.edu. Copyright 2020 by the National Academy of Sciences. All rights reserved. Printed in the United States of America Suggested citation: National Academies of Sciences, Engineering, and Medicine. 2020. Framework for equitable allocation of COVID-19 vaccine. Washington, DC: The National Academies Press. https://doi.org/10.17226/25917. PREPUBLICATION COPY: UNCORRECTED PROOFS Copyright National Academy of Sciences. All rights reserved. Framework for Equitable Allocation of COVID-19 Vaccine The National Academy of Sciences was established in 1863 by an Act of Congress, signed by President Lincoln, as a private, nongovernmental institution to advise the nation on issues related to science and technology. Members are elected by their peers for outstanding contributions to research. Dr. Marcia McNutt is president. The National Academy of Engineering was established in 1964 under the charter of the National Academy of Sciences to bring the practices of engineering to advising the nation. Members are elected by their peers for extraordinary contributions to engineering. Dr. John L. Anderson is president. The National Academy of Medicine (formerly the Institute of Medicine) was established in 1970 under the charter of the National Academy of Sciences to advise the nation on medical and health issues. Members are elected by their peers for distinguished contributions to medicine and health. Dr. Victor J. Dzau is president. The three Academies work together as the National Academies of Sciences, Engineering, and Medicine to provide independent, objective analysis and advice to the nation and conduct other activities to solve complex problems and inform public policy decisions. The National Academies also encourage education and research, recognize outstanding contributions to knowledge, and increase public understanding in matters of science, engineering, and medicine. Learn more about the National Academies of Sciences, Engineering, and Medicine at www.nationalacademies.org. PREPUBLICATION COPY: UNCORRECTED PROOFS Copyright National Academy of Sciences. All rights reserved. Framework for Equitable Allocation of COVID-19 Vaccine Consensus Study Reports published by the National Academies of Sciences, Engineering, and Medicine document the evidence-based consensus on the study’s statement of task by an authoring committee of experts. Reports typically include findings, conclusions, and recommendations based on information gathered by the committee and the committee’s deliberations. Each report has been subjected to a rigorous and independent peer-review process and it represents the position of the National Academies on the statement of task. Proceedings published by the National Academies of Sciences, Engineering, and Medicine chronicle the presentations and discussions at a workshop, symposium, or other event convened by the National Academies. The statements and opinions contained in proceedings are those of the participants and are not endorsed by other participants, the planning committee, or the National Academies. For information about other products and activities of the National Academies, please visit www.nationalacademies.org/about/whatwedo. PREPUBLICATION COPY: UNCORRECTED PROOFS Copyright National Academy of Sciences. All rights reserved. Framework for Equitable Allocation of COVID-19 Vaccine COMMITTEE ON EQUITABLE ALLOCATION OF VACCINE FOR THE NOVEL CORONAVIRUS WILLIAM H. FOEGE (Co-Chair), Emeritus Distinguished Professor of International Health, Rollins School of Public Health, Emory University HELENE D. GAYLE (Co-Chair), President and Chief Executive Officer, The Chicago Community Trust MARGARET L. BRANDEAU, Coleman F. Fung Professor of Engineering, Professor of Medicine (by courtesy), Department of Management Science and Engineering, Stanford University ALISON M. BUTTENHEIM, Associate Professor of Nursing and Health Policy, University of Pennsylvania School of Nursing R. ALTA CHARO, Warren P. Knowles Professor of Law and Bioethics, University of Wisconsin Law School JAMES F. CHILDRESS, University Professor Emeritus, Institute for Practical Ethics and Public Life, University of Virginia ANA V. DIEZ ROUX, Dean and Distinguished University Professor of Epidemiology, Dornsife School of Public Health, Drexel University ABIGAIL ECHO-HAWK (Citizen of the Pawnee Nation), Director, Urban Indian Health Institute, Chief Research Officer, Seattle Indian Health Board CHRISTOPHER ELIAS, President, Global Development Division, Bill & Melinda Gates Foundation BARUCH FISCHHOFF, Howard Heinz University Professor, Department of Engineering and Public Policy, Institute for Politics and Strategy, Carnegie Mellon University DAVID MICHAELS, Professor, Environmental and Occupational Health, Milken Institute School of Public Health, The George Washington University JEWEL MULLEN, Associate Dean for Health Equity, Associate Professor of Population Health and Internal Medicine, The University of Texas at Austin Dell Medical School SAAD B. OMER, Director, Yale Institute for Global Health DANIEL POLSKY, Bloomberg Distinguished Professor of Health Policy and Economics, Carey Business School and Bloomberg School of Public Health, Johns Hopkins University SONJA RASMUSSEN, Professor of Pediatrics, Epidemiology, and Obstetrics and Gynecology, College of Medicine and College of Public Health and Health Professions, University of Florida ARTHUR L. REINGOLD, Division Head, Epidemiology and Biostatistics, Professor of Epidemiology, School of Public Health, University of California, Berkeley REED V. TUCKSON, Managing Director, Tuckson Health Connections, LLC MICHAEL R. WASSERMAN, President, California Association of Long Term Care Medicine Study Staff LISA BROWN, Study Director BENJAMIN KAHN, Associate Program Officer ELIZABETH FINKELMAN, Senior Program Officer AURELIA ATTAL-JUNCQUA, Associate Program Officer PREPUBLICATION COPY: UNCORRECTED PROOFS v Copyright National Academy of Sciences. All rights reserved. Framework for Equitable Allocation of COVID-19 Vaccine EMMA FINE, Associate Program Officer REBECCA CHEVAT, Senior Program Assistant ROSE MARIE MARTINEZ, Senior Director, Board on Population Health and Public Health Practice ANDREW M. POPE, Senior Director, Board on Health Sciences Policy Science Writer ANNA NICHOLSON PREPUBLICATION COPY: UNCORRECTED PROOFS vi Copyright National Academy of Sciences. All rights reserved. Framework for Equitable Allocation of COVID-19 Vaccine Reviewers This Consensus Study Report was reviewed in draft form by individuals chosen for their diverse perspectives and technical expertise.
Recommended publications

  • Biden-Harris Transition Announces COVID-19 Advisory Board

    BIDEN-HARRIS TRANSITION The President-Elect The Vice President-Elect Priorities Transition Español NOVEMBER 09, 2020 PRESS RELEASES Biden-Harris Transition Announces COVID-19 Advisory Board Leading Public Health and Scientific Experts to Advise the Transition on COVID-19 Response WASHINGTON – Today, the Biden-Harris Transition announced the formation of the Transition COVID-19 Advisory Board, a team of leading public health experts who will advise President-elect Biden, Vice President-elect Harris, and the Transition’s COVID-19 staff. The Transition COVID-19 Advisory Board will be led by co-chairs Dr. David Kessler, Dr. Vivek Murthy, and Dr. Marcella Nunez-Smith. Dr. Beth Cameron and Dr. Rebecca Katz are serving as advisors to the Transition on COVID-19 and will work closely with the Advisory Board. “Dealing with the coronavirus pandemic is one of the most important battles our administration will face, and I will be informed by science and by experts,” said President-elect Biden. “The advisory board will help shape my approach to managing the surge in reported infections; ensuring vaccines are safe, effective, and distributed efficiently, equitably, and free; and protecting at-risk populations.” New cases are rising in at least 40 states, with more than 9.3 million total infections and more than 236,000 deaths. President-elect Biden has pledged to bring leadership to the COVID pandemic, which continues to claim thousands of lives each week, by curbing the spread of the disease, providing free treatment to those in need, and elevating the voices of scientists and public health experts. The COVID-19 Advisory Board will help guide the Biden-Harris Transition in planning for the President-elect’s robust federal response.
  • Chicago Department of Public Health

    Chicago Department of Public Health

    Chicago Department of Public Health City of Chicago Chicago Department of Public Health Rahm Emanuel, Mayor Communicable Disease Program Julie Morita, MD, Commissioner Invasive Meningococcal Disease in Men Who Have Sex with Men Date: June 3, 2015 To: Infection Preventionists, Emergency Department, Infectious Disease, Primary Care, Internal Medicine, Family Medicine, Pediatrics, Critical Care physicians and Laboratory personnel From: Stephanie Black, MD, MSc, Medical Director, Communicable Diseases Program Sarah Kemble, MD, Medical Director, Communicable Diseases Program Since mid-May 2015, the Chicago Department of Public Health (CDPH) has been actively investigating reports of 3 confirmed cases of invasive meningococcal disease (IMD) in men who have sex with men (MSM), one of which was fatal. All 3 N. meningitidis isolates are serogroup C. Characteristics of cases include HIV diagnosis or use of on-line “hook-up” apps to seek sexual partners (e.g., Grindr, Jack’d, Adam4Adam). Among HIV positive MSM in Chicago, the annual incidence rate of IMD in 2015 has reached approximately 23/100,000, surpassing the Advisory Committee on Immunization Practices (ACIP) recommended threshold of 10/100,000 for initiating a meningococcal vaccination campaign.1 Due to this cluster, CDPH is recommending meningococcal vaccination for: 1) HIV-positive MSM and, 2) MSM regardless of HIV status, who have close or intimate contact with anonymous partners or seek sexual partners through use of on-line “hook-up” apps. In 2003, an outbreak of IMD occurred among MSM in Chicago.2 From 2010-2013 an outbreak of IMD in MSM was identified in New York City; cases included HIV-positive MSM and MSM who used digital applications to meet sexual partners.3 Obtaining meningococcal vaccine: Men in the risk categories defined above may obtain vaccine through one of 3 methods: Primary healthcare provider Pharmacies CDPH Fast-track clinics located at Englewood Neighborhood Health Center: 641 W.
  • ASE Lobbyist Confernce Federal Update Chris Rogers September

    ASE Lobbyist Confernce Federal Update Chris Rogers September

    ASE Lobbyist Conference Federal Update Chris Rogers November 2020 Overview ■ Biden Transition (5-step plan to reopen schools) □ Controlling the Virus □ National Safety Guidelines □ Emergency Funding for Public Schools □ High-Quality Learning during the COVID-19 Pandemic □ COVID-19 Educational Equity Gap ■ Biden K-12 Education Proposals & Outlook ■ Lame Duck Session □ FY 2021 Appropriations □ COVID 5 2 Controlling the Virus Implement nationwide testing-and-tracing, including doubling the number of drive- Implement through testing sites; Establish a sustainable supply chain for PPE, including fully utilizing the Defense Establish Production Act to ensure enough masks are for every school in America every day; Protect Protect older Americans and others at high-risk populations; Provide Provide schools and small businesses with the resources they need to reopen safely. 3 National Safety Guidelines ■ Biden agrees with AASA, schools in areas with high levels of COVID-19 community spread should not be compelled to reopen against the judgement of local experts. Currently, current lack of clarity is paralyzing for schools. ■ Biden plans to support the efforts of Local Education Agencies by issuing federal reopening guidelines that answer basic questions many school systems have. 1. How low does the community infection rate need to be to reopen and at what point should schools shut down again if cases rise? 2. What are safe maximum class sizes? 3. 4If schools cannot accommodate everyone, who should return to the classroom first? Emergency Funding for Public Schools Biden’s 3rd step is to provide additional funding to public schools to contend with the coronavirus outbreak. Thus far, Biden has requested the following aid to support LEA’s reopening strategies.

  • Trump to Shut Off Tiktok, Wechat to New U.S. Users on Sunday

    For news and information consider- If you would like to share news or news organization events, and school Mr. Lee’s Commen- ation, please send to If information with our readers, please news to us includinig your name and [email protected] tary and Dairy send the unique stories, business phone number in case more informa- tion is needed. or contact John Robbins 832-280-5815 Jun Gai 281-498-4310 Publisher: Wea H. Lee President: Catherine Lee Editor: John Robbins, Jun Gai Address: 11122 Bellaire Blvd., Houston, TX 77072 E-mail: [email protected] Southern Daily News is published by Southern News Group Daily Inside C2 Saturday September 19 2020 | www.today-america.com | Southern News Group Trump to shut off TikTok, WeChat to new U.S. users on Sunday WASHINGTON (Reuters) - The Trump administration WeChat developer Tencent Holdings’ called the order will ban WeChat and video-sharing app TikTok from U.S. “We have some great options and maybe we can keep a lot of “unfortunate” but said it “will continue to discuss with app stores starting Sunday night, a move that will block people happy,” Trump told reporters. “We have to have the total the government and other stakeholders in the U.S. ways Americans from downloading the Chinese-owned plat- security from China.” to achieve a long-term solution.” forms over concerns they pose a national security threat. Commerce Secretary Wilbur Ross told Fox Business Network that The Commerce Department order bars Apple Inc’s app The bans, announced on Friday, affect only new “the basic TikTok will stay intact until Nov.
  • Emerging Leaders in Biosecurity Initiative

    Emerging Leaders in Biosecurity Initiative

    Emerging Leaders in Biosecurity Initiative Class of 2017 A competitive fellowship program created to identify, develop, and provide networking opportunities Yearbook for the next generation of leaders in biosecurity. Emerging Leaders in Biosecurity Initiative Contents Letter: 3 Thomas V. Inglesby, Director; Anita Cicero, Deputy Director, Johns Hopkins Center for Health Security Executive Steering Committee 5 Class of 2017 Fellows 9-35 ELBI 2017 Year in Review 36-37 ELBI Program Staff 41 ELBI Alumni 42 Cover and Inside Cover Photo Overlay: Swine Flu Strain Virus Particles. Col- orized transmission electron micrograph of negatively stained SW31 (swine strain) influenza virus particles. Credit: NIAID Emerging Leaders in Biosecurity Initiative The ELBI Fellowship program is made possible through financial support from the Open Philanthropy Project, under management by the Johns Hopkins Center for Health Security, and with the leadership of the ELBI Executive Steering Committee. For more information, please visit the ELBI website: http://www.centerforhealthsecurity.org/our-work/emergingbioleaders Center for Health Security “Modern conditions make the scenario of a global pandemic more likely. Humans are encroaching on animal environments, raising chances for pathogens to adapt from animals to people. An increasing share of the planet lives in megacities, heightening the likelihood of person-to-person transmission of pathogens. The movement of people and microbes around the globe is more efficient than ever. The recent outbreaks of SARS, MERS, and Ebola are only small glimpses of how quickly a deadly virus can spread.” Tom Inglesby and Benjamin Haas Foreign Affairs November 21, 2017 Middle East Respiratory Syndrome Coronavirus particle envelope proteins immunolabeled with Rabbit HCoV-EMC/2012 primary antibody and Goat an- 1 ti-Rabbit 10 nm gold particles.
  • SYRA MADAD, D.H.Sc, M.Sc., MCP

    SYRA MADAD, D.H.Sc, M.Sc., MCP

    SYRA MADAD, D.H.Sc, M.Sc., MCP Syra Madad, D.H.Sc., M.Sc., MCP is nationally recognized leader in public health and special pathogen preparedness and response. She is Senior Director, System-wide Special Pathogens Program at New York City Health + Hospitals, the nation’s largest municipal healthcare delivery system overseeing special pathogen preparedness and response efforts across 11 acute care hospitals in addition to post-acute/long-term care facilities and ambulatory care sites. She is Principal Investigator of NYC Health + Hospitals Center for Global Healthcare Preparedness to Special Pathogens. In addition, Dr. Madad is Core Faculty in the National Ebola Training and Education Center (NETEC), funded by the Centers for Disease Control and Prevention (CDC) and the Assistant Secretary for Preparedness and Response (ASPR) and Assistant Professor in the Graduate Biotechnology/Biodefense Program at the University of Maryland. She is an Alumni Fellow at Johns Hopkins Bloomberg School of Public Health, Center for Health Security’s Emerging Leaders in Biosecurity Program and the Federal Bureau of Investigation’s Behavioral Informatics & Technological Enterprise Studies Program. Dr. Madad earned her Doctoral degree in Health Science with a concentration in Global Health from Nova Southeastern University, graduating with Alpha Eta Health Science Honor Society status. She obtained her Master of Science degree in Biotechnology with a concentration in Biodefense and Biosecurity and Bachelor of Science degree in Psychology from the University of Maryland. Dr. Madad holds numerous professional certifications, licenses and training certificates including Master Continuity Practitioner Certification (FEMA), Advanced Emergency Planning Certification, All Hazard Response (CBRNE) Training for Laboratory Personnel, Biosafety Level III Training, and Identification of the Primary Select Agents of Bioterrorism Training.
  • Clinical Laboratory Preparedness and Response Guide

    Clinical Laboratory Preparedness and Response Guide

    TABLE OF CONTENTS Table of Contents ...................................................................................................................................................................................... 2 State Information ....................................................................................................................................................................................... 7 Introduction .............................................................................................................................................................................................. 10 Laboratory Response Network (LRN) .......................................................................................................................................... 15 Other Emergency Preparedness Response Information: .................................................................................................... 19 Radiological Threats ......................................................................................................................................................................... 21 Food Safety Threats .......................................................................................................................................................................... 25 BioWatch Program ............................................................................................................................................................................ 27 Bio Detection Systems
  • May 25, 2017 the Honorable Richard Durbin, United States Senator 711

    May 25, 2017 the Honorable Richard Durbin, United States Senator 711

    May 25, 2017 The Honorable Richard Durbin, United States Senator 711 Hart Senate Building Washington, D.C. 20510 The Honorable Tammy Duckworth, United States Senator 524 Hart Senate Building Washington, D.C. 20510 Dear Senators Durbin and Duckworth, The undersigned local health departments are writing with an urgent request for you to reject the American Health Care Act (AHCA) on behalf of the 1.2 million Illinois residents who stand to lose coverage and the millions more who will experience reductions in both individual health care and community public health options. Thank you for your steadfast support of the benefits Illinois has seen under the Affordable Care Act and your public opposition to the AHCA. As you know, those most impacted by these changes will be the most vulnerable residents of our counties and cities, including children with serious underlying health conditions; people with chronic illnesses; residents approaching retirement age; low-income, working adults; and people with substance use and mental health disorders. As a result of the Medicaid expansion made available under the Affordable Care Act, more than 650,000 additional low-income Illinois residents have life-saving health insurance in 2017. The AHCA would turn the clock back on this progress, returning Illinois to a time when health care coverage was out of reach for too many of our most vulnerable residents. Today, thanks to our progress, these individuals and their families can access high-quality, comprehensive health insurance coverage to ensure they can meet their health care needs without fear of financial ruin. To be clear, the AHCA is bad for Illinois families and bad for Illinois communities.
  • Framework on Accumulating Evidence Across Outbreaks

    Framework on Accumulating Evidence Across Outbreaks

    Framework on accumulating evidence across outbreaks NATALIE DEAN DEPARTMENT OF BIOSTATISTICS UNIVERSITY OF FLORIDA WHO R&D BLUEPRINT CONSULTATION ON CLINICAL TRIAL DESIGNS NOVEMBER 29, 2018, GENEVA Kennedy et al. (2016) DOI: 10.1177/1740774515621037 2 Figure: Weekly incidence of Ebola in Guinea 2014–15, and key dates in the ring vaccination trial 3 doi:10.1126/science.aav3996 4 National Academies of Sciences, Engineering, and Medicine (2017) https://doi.org/10.17226/24739 5 http://www.who.int/emergencies/mers-cov/epi-18-september-2018.png 6 Motivation Outbreaks are of unpredictable size and duration All outbreaks represent an opportunity to advance research and development efforts There is considerable risk that trials will be underpowered and results from trials terminated due to low accrual will be inconclusive Prejudgment of promising but inconclusive results can: . Impact decision-making of caregivers and policy makers . Jeopardize the conduct of future confirmatory trials 7 Recommended approach We advocate for the use of a “master protocol” to preserve data confidentiality and trial integrity until the scientific aims have been reliably addressed Master protocol = conventional clinical trial designed to extend across multiple sites and outbreaks Trial results are released only following the advice of an independent data monitoring committee (e.g. stop for efficacy, futility, reached target # of endpoints) and not due to lack of recruitment 8 Practical considerations Multi-site trial in high-risk areas with opportunity to add sites
  • Legal-Graphics' 6-26-21 COVID Timeline

    Legal-Graphics' 6-26-21 COVID Timeline

    Number of days since first sign of virus Overview: Year 2 of COVID Year 2 Nov. 23, 2020 Dec. 3, 2020 Dec. 11, 2020 Dec. 21, 2020 Dec. 30, 2020 Jan. 7, 2021 Jan.Jan. 14,7, 2021 2021 of COVID-19 Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths over 1,400,000 over 1,500,000 over 1,600,000 over 1,700,000 over 1,800,000 over 1,900,000 over 1,900,0002,000,000 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 Link to Nov. 16, 2020 Nov. 18, 2020 Nov. 21, 2020 Nov. 25, 2020 Nov. 27, 2020 Nov. 30, 2020 Dec. 3, 2020 Dec. 6, 2020 Dec. 8, 2020 Dec. 11, 2020 Dec. 14, 2020 Dec. 17, 2020 Dec. 21, 2020 Dec. 22, 2020 Dec. 26, 2020 Dec. 29, 2020 Dec. 31, 2020 Jan. 3, 2021 Jan. 5, 2021 Jan. 8, 2021 Jan. 11, 2021 Jan. 13, 2021 Jan. 17, 2021 Source Moderna says data FDA allows US cases top Picture of US Demand for live Moderna to request Map showing US UK gears up for Chart of cumulative Pfizer vaccine to be How do the Pfizer Vaccinations reach How the Pfizer Vaccines across Could AZD7442 Map showing How vaccinations Interactive US Map It’s lockdown No.
  • Turtles Without Borders Sea Turtles Are Rebounding, but Much Work Remains Fall 2019, Vol

    Turtles Without Borders Sea Turtles Are Rebounding, but Much Work Remains Fall 2019, Vol

    FALL 2019 Turtles Without Borders Sea Turtles Are Rebounding, But Much Work Remains Fall 2019, Vol. 24, No. 3 Extracts Research briefs 5 Turtles Without Borders Sea turtles are rebounding, but much work remains 14 Center of Excellence UF grows $10 million grant into $1.7 billion gene therapy 24 company Brammer Bio RandallRuiz; cover photo, DavidTroeger Dr. Kent Fuchs President Dr. David Norton Vice President for Research Board of Trustees Mori Hosseini, Chair David L. Brandon James W. Heavener Leonard H. Johnson Thomas G. Kuntz Michael C. Murphy Daniel T. O’Keefe Rahul Patel Marsha D. Powers Jason J. Rosenberg Robert G. Stern Ray G. Thomas Anita G. Zucker Explore is published by UF Research. Opinions expressed do not reflect the official views of the university. Use of trade names implies no endorsement by the University of Florida. © 2019 University of Florida. The Writing Life explore.research.ufl.edu The University of Florida’s Editor: creative writing program Joseph M. Kays nurtures and pushes its [email protected] graduate students 30 Art Director: Katherine Kinsley-Momberger Design and Illustration: Katherine Kinsley-Momberger Ivan J. Ramos Mr. IPO Writers: Jay Ritter has spent his career Joseph Kays Cindy Spence tracking the emergence of new public companies Photography: John Jernigan 38 Charlotte Kesl Web Editor: Jewel Midelis Copy Editor: Bruce Mastron The Conversation Printing: Changing Tech's Face StorterChilds Printing, Gainesville Member of the University Research Magazine Association 42 www.urma.org Building a Better World Being forward-focused on a worthy goal is an essential attribute of any individual or organization that seeks relevance and impact in a complex endeavor.
  • SYRA MADAD, D.H.Sc, M.Sc., MCP

    SYRA MADAD, D.H.Sc, M.Sc., MCP

    SYRA MADAD, D.H.Sc, M.Sc., MCP Syra Madad, D.H.Sc., M.Sc., MCP is nationally recognized public health leader and epidemiologist in infectious disease and special pathogen preparedness and response. She is Senior Director, System-wide Special Pathogens Program at New York City Health + Hospitals, the nation’s largest municipal healthcare delivery system overseeing special pathogen preparedness and response efforts across 11 acute care hospitals in addition to post-acute/long-term care facilities and ambulatory care sites. She is Principal Investigator of NYC Health + Hospitals Institute of Diseases and Disaster Management and Health & Safety Lead of the Enhanced Special Investigations Unit of NYC Test & Trace Corp. In addition, Dr. Madad is Core Faculty in the National Emerging Special Pathogens Training and Education Center (NETEC), funded by the Centers for Disease Control and Prevention (CDC) and the Assistant Secretary for Preparedness and Response (ASPR). She is a Fellow at Harvard University’s Belfer Center for Science and Select Media Highlights on Dr. International Affairs, Adjunct Senior Fellow at the Federation of American Madad: • Fortune 40 Under 40 Scientists and part of their COVID19 Taskforce, Alumni Fellow at Johns • Netflix’s Pandemic: How to Prevent Hopkins Bloomberg School of Public Health, Center for Health Security’s an Outbreak Emerging Leaders in Biosecurity Program and Alumni Senior Fellow in the • Discovery The Vaccine: Conquering COVID Federal Bureau of Investigation’s Behavioral Informatics & Technological • Elemental 50 Experts to Trust in a Enterprise Studies Program. Pandemic • NY Magazine Feature on Dr. Syra Dr. Madad earned her Doctoral degree in Health Science with a Madad concentration in Global Health from Nova Southeastern University, • CNN: Disease Detectives graduating with Alpha Eta Health Science Honor Society status.